Abstract
This patent application pertains to a novel class of peptide triagonists, generally represented by Formula I. These peptides exhibit selective activities toward GIPR (gastric inhibitory polypeptide receptor), GLP-1R (glucagon-like peptide-1 receptor), and GCGR (glucagon receptor). The unique pharma-cological profile of these triagonists offers promising therapeutic potential for the management of various conditions, including type 2 diabetes mellitus (T2DM), weight management, nonalcoholic fatty liver disease, etc.